This page collects WhisperX intelligence signals tagged #CAR-T. It is designed for humans, search engines, and AI agents: each item links to a canonical source-backed record with sector, source, timestamp, credibility, and exportable structured data.
Allogene Therapeutics is approaching a pivotal moment for its 'off-the-shelf' CAR-T therapy, with an early but critical study readout on the horizon. This data point represents a significant test for the company's core technology platform, which aims to revolutionize cancer treatment by moving away from personalized, p...
Five years ago, a single, desperate case in Germany shattered a core assumption in immunology. Georg Schett, a physician-scientist, faced a young lupus patient near death and a radical idea: using engineered CAR-T cells, a cancer therapy, to treat an autoimmune disease. The prevailing fear was that these powerful T cel...
Allogene Therapeutics' experimental off-the-shelf CAR-T therapy has demonstrated a significant advantage in clearing residual cancer cells in patients with B-cell lymphoma, hitting a key interim goal in a pivotal Phase 3 trial. Preliminary data released Monday show the treatment, cema-cel, achieved minimal residual dis...
New clinical data from Allogene Therapeutics is bolstering the case for its 'off-the-shelf' CAR-T therapy, a potential paradigm shift in treating B-cell lymphoma. Unlike personalized CAR-T treatments, which are manufactured from a patient's own cells, Allogene's approach uses donor cells, aiming for a ready-made, more ...
항암세포치료제 전문기업 큐로셀이 대규모 자금 조달에 나섰다. 회사는 4월 17일 무기명식 이권부 무보증 사모 전환사채(CB)를 총액 363억5000만원 규모로 발행하기로 결정했다고 공시했다. 이번 자금 조달의 핵심 목적은 운영자금 확보로, 그 중 348억5000만원은 고형암 CAR-T 치료제 개발을 포함한 연구개발(R&D) 투자에 집중적으로 사용될 예정이다. 이는 회사의 핵심 파이프라인에 대한 대규모 투자를 의미하며, 향후 성장 동력을 확보하기 위한 전략적 움직임으로 해석된다. 발행된 전환사채의 만기는 2031년 4월 27일로 장기적인 자금 조달 구조를 갖췄다. 주...
At the American Association for Cancer Research (AACR) annual meeting, a bold and potentially controversial clinical strategy is taking center stage. Investigators from the Dana-Farber Cancer Institute presented early-phase data showing a deep response when using the CAR-T therapy Carvykti to treat patients with smolde...